An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch
Open Access
- 15 February 2005
- journal article
- Published by Springer Nature in BMC Hematology
- Vol. 5 (1) , 3
- https://doi.org/10.1186/1471-2326-5-3
Abstract
Background: Rotational thromboelastography (ROTEG) has been proposed as a monitoring tool that can be used to monitor treatment of hemophilia with recombinant factor VIIa (rFVIIa). In these studies special non-standard reagents were used as activators of the coagulation. The aim of this study was to evaluate if standard ROTEG analysis could be used for monitoring of effects of recombinant factor VIIa (rFVIIa) on Hydroxy Ethyl Starch-induced dilutional coagulopathy. Methods: The study was performed in vitro on healthy volunteers. Prothrombin time (PT) and ROTEG analysis were performed after dilution with 33% hydroxy ethyl starch and also after addition of rFVIIa to the diluted blood. Results: PT was impaired with INR changing from 0.9 before dilution to 1.2 after dilution while addition of rFVIIa to diluted blood lead to an overcorrection of the PT to an International Normalized Ratio (INR) value of 0.6 (p = 0.01). ROTEG activated with the contact activator ellagic acid was impaired by hemodilution (p = 0.01) while addition of rFVIIa had no further effects. ROTEG activated with tissue factor (TF) was also impaired by hemodilution (p = 0.01) while addition of rFVIIa lead to further impairment of the coagulation (p = 0.01). Conclusions: The parameters affected in the ROTEG analysis were Clot Formation Time and Amplitude after 15 minutes while the Clotting Time was unaffected. We believe these effects to be due to methodological problems when using standard activators of the coagulation in the ROTEG analysis in combination with rFVIIa.Keywords
This publication has 30 references indexed in Scilit:
- Thromboelastography and recombinant factor VIIa—hemophilia and beyondSeminars in Hematology, 2004
- Use of Recombinant Factor VIIa for Bleeding in Children with Glanzmann ThrombastheniaPediatric Hematology and Oncology, 2003
- The in vitro effects of crystalloids and colloids on coagulationAnaesthesia, 2002
- Management and monitoring of recombinant activated factor VIIBlood Coagulation & Fibrinolysis, 2000
- The Effect of In Vitro Hemodilution with Gelatin, Dextran, Hydroxyethyl Starch, or Ringer’s Solution on Thrombelastograph®Anesthesia & Analgesia, 2000
- In Vitro Effects of Different Medium Molecular Hydroxyethyl Starch Solutions and Lactated Ringer’s Solution on Coagulation Using SONOCLOTAnesthesia & Analgesia, 2000
- Compromised Blood CoagulationAnesthesia & Analgesia, 1998
- Hydroxyethyl starch impairsin vitrocoagulationActa Anaesthesiologica Scandinavica, 1998
- Lethal Injuries and Time to Death in a Level I Trauma Center 1 1The views expressed in this article are those of the author(s) and do not reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government.Journal of the American College of Surgeons, 1998
- Hemostasis in Massively Transfused Trauma PatientsAnnals of Surgery, 1979